High-dose chemotherapy and transplantation of autologous CD34+ selected stem cells for progressive systemic sclerosis adjusted to cardiac and lung manifestation: An open-label, non-inferiority phase 2 trial
This adapted regimen showed comparable 3y-OS in patients with advanced organ involvement who would have been excluded from prior trials. While feasibility is demonstrated, aHSCT in this high-risk population remains associated with substantial risk, and efficacy cannot be definitively established. Further studies are warranted.
Authors
- Stefan Wirths (ORCID: https://orcid.org/0000-0003-2494-9862)
- Ann‐Christin Pecher (ORCID: https://orcid.org/0000-0003-0201-0686)
- Reinhild Klein (ORCID: https://orcid.org/0000-0002-6111-3901)
- Patrick Krumm (ORCID: https://orcid.org/0000-0003-1705-8439)
- Marc Schmalzing (ORCID: https://orcid.org/0000-0002-3289-2299)
- Claudia Lengerke (ORCID: https://orcid.org/0000-0001-5442-2805)
- K. Peis
- W. Vogel
- J. Henes
- Ina Koetter
Institutions
- Universität Hamburg (DE)
- University of Würzburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- STZ eyetrial (DE)
- Center for Rheumatology (US)
- University of Tübingen (DE)
Publication Details
- Journal
- Joint Bone Spine
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1016/j.jbspin.2026.106032
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00